Supplemental Information. Checkpoint Blockade Immunotherapy. Induces Dynamic Changes. in PD-1 CD8 + Tumor-Infiltrating T Cells

Similar documents
Supplemental Figure 1

Nature Immunology: doi: /ni Supplementary Figure 1. Transcriptional program of the TE and MP CD8 + T cell subsets.

Supplementary Figure 1. Efficiency of Mll4 deletion and its effect on T cell populations in the periphery. Nature Immunology: doi: /ni.

Nature Immunology: doi: /ni Supplementary Figure 1. RNA-Seq analysis of CD8 + TILs and N-TILs.

Nature Immunology: doi: /ni Supplementary Figure 1. Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice.

Spleen. mlns. E Spleen 4.1. mlns. Spleen. mlns. Mock 17. Mock CD8 HIV-1 CD38 HLA-DR. Ki67. Spleen. Spleen. mlns. Cheng et al. Fig.

Supplementary Table 1 Clinicopathological characteristics of 35 patients with CRCs

Supplementary Figure S1. PTPN2 levels are not altered in proliferating CD8+ T cells. Lymph node (LN) CD8+ T cells from C57BL/6 mice were stained with

Tim-3 as a target for tumor immunotherapy

Supplemental Information. IRF-5 Promotes Cell Death in CD4 T Cells. during Chronic Infection

Supplementary Figure 1. Characterization of basophils after reconstitution of SCID mice

Nature Immunology: doi: /ni Supplementary Figure 1. Id2 and Id3 define polyclonal T H 1 and T FH cell subsets.

Supplementary Figure 1. mrna expression of chitinase and chitinase-like protein in splenic immune cells. Each splenic immune cell population was

Dendritic cells in cancer immunotherapy Aimin Jiang

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY FIGURE 1

Supplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured

pplementary Figur Supplementary Figure 1. a.

Supplemental Materials for. Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to. FTY720 during neuroinflammation

Supplementary Figures

% of live splenocytes. STAT5 deletion. (open shapes) % ROSA + % floxed

Akt and mtor pathways differentially regulate the development of natural and inducible. T H 17 cells

Supplementary Figure 1.

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-

Supplementary Figure 1. Immune profiles of untreated and PD-1 blockade resistant EGFR and Kras mouse lung tumors (a) Total lung weight of untreated

well for 2 h at rt. Each dot represents an individual mouse and bar is the mean ±

B220 CD4 CD8. Figure 1. Confocal Image of Sensitized HLN. Representative image of a sensitized HLN

Nature Immunology: doi: /ni Supplementary Figure 1. Characteristics of SEs in T reg and T conv cells.

HD1 (FLU) HD2 (EBV) HD2 (FLU)

Supplementary Materials for

Tbk1-TKO! DN cells (%)! 15! 10!

Nature Immunology: doi: /ni Supplementary Figure 1. Cytokine pattern in skin in response to urushiol.

and follicular helper T cells is Egr2-dependent. (a) Diagrammatic representation of the

Supplemental Figure Legends

Supplementary Materials

Dual Targeting Nanoparticle Stimulates the Immune

Combined Rho-kinase inhibition and immunogenic cell death triggers and propagates immunity against cancer

Eosinophils are required. for the maintenance of plasma cells in the bone marrow

Supplemental Materials

Mst1 regulates integrin-dependent thymocyte trafficking and antigen recognition in the thymus

Defective STAT1 activation associated with impaired IFN-g production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2

Supplementary Figure 1. Double-staining immunofluorescence analysis of invasive colon and breast cancers. Specimens from invasive ductal breast

Supplementary Figure 1

NK cell flow cytometric assay In vivo DC viability and migration assay

SUPPLEMENTARY INFORMATION

Therapeutic PD L1 and LAG 3 blockade rapidly clears established blood stage Plasmodium infection

Supplementary Fig. 1: Ex vivo tetramer enrichment with anti-c-myc beads

Supplementary Figure 1 IL-27 IL

Preclinical investigation of the promise and challenges of agonistic anti-gitr antibody therapy. Amy Beebe Merck Research Laboratory March 16, 2017

Supplementary figure 1

Hua Tang, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder I Nakaya, Kousik

Nature Medicine: doi: /nm.3922

Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors

Appendix Figure S1 A B C D E F G H

Supplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12

Supplementary Figure 1. Deletion of Smad3 prevents B16F10 melanoma invasion and metastasis in a mouse s.c. tumor model.

x Lymphocyte count /µl CD8+ count/µl 800 Calculated

Supporting Information Table of Contents

Supplementary. presence of the. (c) mrna expression. Error. in naive or

L1 on PyMT tumor cells but Py117 cells are more responsive to IFN-γ. (A) Flow

Supplementary Figure 1. Efficient DC depletion in CD11c.DOG transgenic mice

Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs

SUPPLEMENTARY INFORMATION

Supplemental Information. CD4 + CD25 + Foxp3 + Regulatory T Cells Promote. Th17 Cells In Vitro and Enhance Host Resistance

Supplementary Figure 1 Protease allergens induce IgE and IgG1 production. (a-c)

activation with anti-cd3/cd28 beads and 3d following transduction. Supplemental Figure 2 shows

CD44

ILC1 and ILC3 isolation and culture Following cell sorting, we confirmed that the recovered cells belonged to the ILC1, ILC2 and

NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies

Supplemental Information. Aryl Hydrocarbon Receptor Controls. Monocyte Differentiation. into Dendritic Cells versus Macrophages

Supplemental Table I.

Supplemental Information. Genomic Characterization of Murine. Monocytes Reveals C/EBPb Transcription. Factor Dependence of Ly6C Cells

Online Appendix Material and Methods: Pancreatic RNA isolation and quantitative real-time (q)rt-pcr. Mice were fasted overnight and killed 1 hour (h)

fl/+ KRas;Atg5 fl/+ KRas;Atg5 fl/fl KRas;Atg5 fl/fl KRas;Atg5 Supplementary Figure 1. Gene set enrichment analyses. (a) (b)

Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis

MATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All

BMDCs were generated in vitro from bone marrow cells cultured in 10 % RPMI supplemented

Supplementary Figure 1. ETBF activate Stat3 in B6 and Min mice colons

CD80 and PD-L2 define functionally distinct memory B cell subsets that are. Griselda V Zuccarino-Catania, Saheli Sadanand, Florian J Weisel, Mary M

The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23- induced production of the cytokine GM-CSF

Reviewers' comments: Reviewer #1 (Remarks to the Author):

Supporting Information

Supplementary Figure 1

Supporting Information

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School

Supporting Information

Supplementary Materials for

Supplementary Information. Tissue-wide immunity against Leishmania. through collective production of nitric oxide

SUPPLEMENTARY INFORMATION

MHC class I MHC class II Structure of MHC antigens:

Supplementary Figure 1

Supplementary Materials for

Supplementary Information

Supplementary Figure Legends. group) and analyzed for Siglec-G expression utilizing a monoclonal antibody to Siglec-G (clone SH2.1).

Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood

NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology

Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.

Supplementary Material

Supplementary Figure 1. Example of gating strategy

Depletion of FAP + cells reduces immunosuppressive cells and improves metabolism and functions CD8 + T cells within tumors

Transcription:

Immunity, Volume 50 Supplemental Information Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1 CD8 + Tumor-Infiltrating T Cells Sema Kurtulus, Asaf Madi, Giulia Escobar, Max Klapholz, Jackson Nyman, Elena Christian, Mathias Pawlak, Danielle Dionne, Junrong Xia, Orit Rozenblatt-Rosen, Vijay K. Kuchroo, Aviv Regev, and Ana C. Anderson

Figure S1 (Related to Figure 4). Marker expression and poly-functionality in PD-1 CD8 + TIL subsets. A) Representative flow cytometry data showing expression of CD62L, CX3CR1, and KLRG1 within PD-1 CD8 + TILs. (B C) Frequency (mean ± SEM) of IL-2 + IFN-γ + (B) and TNF-α + IFN-γ + (C) cells among the indicated PD-1 CD8 + TIL populations after ex vivo stimulation with 5 µg/ml OVA 257 264 peptide. ***p < 0.001 and ****p < 0.0001, One-way ANOVA, Tukey s multiple comparison test.

Figure S2 (Related to Figure 5). Changes in PD-1 CD8 + TIL subsets after Tim3 + PD-1 blockade. A) Numbers (mean ± SEM) of the indicated PD1 CD8 + TIL subsets in tumors from Tim3 + PD1 blockade- or isotype-treated MC38OVA-bearing mice overtime. **p < 0.01, ***p < 0.001, Mann Whitney U test. B) Frequency (mean ± SEM) of the indicated PD-1 CD8 + TIL subsets from Tim3 + PD-1 blockade- or isotype-treated B16F10-bearing mice. *p < 0.05, ****p < 0.0001 Mann Whitney U test. Data are from two independent experiments.

Figure S3 (Related to Figure 6). Analysis of single-cell RNA profiles from Tim-3 + PD-1 blockade- versus isotype-treated mice. A) Bar graphs show the frequency of cells present in each cluster from isotype (blue) or anti-tim- 3 + PD-1 (red)-treated groups, *p < 0.001, Fisher s exact test. B) I, tsne plot showing projection of an effector CD8 + T cell signature (Kaech et al., 2002), II) projection of the CD62L hi Slamf7 naïve-like signature, III) projection of the Slamf7 hi CX3CR1 memory-precursor-like signature, and IV) projection of the Slamf7 hi CX3CR1 + effector-like signature onto the PD-1 - CD8 + TILs single-cell data. Color scale indicates the signature score. The contour marks the region of highly scored cells by taking into account only those cells that have a signature score above the 10th percentile. Cells with a statistically significant score are marked with a + (Methods). C) I) tsne plot showing projection of IFNβ (Iwata et al., 2017), II) IFNγ (Iwata et al., 2017), III) IL-6 (Hirahara et al., 2015), and IV) IL-12 (Agarwal et al., 2009) signatures onto the PD-1 CD8 + TILs single-cell data. Color scale indicates the signature score. The contour marks the region of highly scored cells by taking into account only those cells that have a signature score above the 10th percentile (Methods). Cells with a statistically significant score are marked with a +. Violin plots show the cytokine signature score from isotype- vs Tim-3 + PD-1 blockade-treated mice. ***p < 0.0001, t-test. D) Dot plot showing expression of the indicated genes in each of the single-cell clusters. Color scale indicates the expression score of each gene in the indicated cluster. Circle size indicates the percentage of cells that expresses the gene within the indicated cluster.

Figure S4 (Related to Figure 6). Naïve, effector, and memory-precursor-like cells in patients. A) GSEA of signatures from human CD8 + TILs (Methods) in the memory-precursor-like CD62L Slamf7 hi CX3CR1 PD-1 (green) and effector-like CD62L Slamf7 hi CX3CR1 + PD-1 (blue) CD8 + TIL subsets. B) Projection of several human signatures (Methods) onto our single-cell clusters (Figure 6A, panel II). The color scale shows the average expression signature score of all the cells that compose the cluster. Circle size indicates the percentage of the cells in each cluster that expresses a signature above the median and the dark borders indicate clusters that were either significantly concentrated or depleted of high-scoring cells (FDR- adjusted P value < 0.05, t-test). A + sign indicates clusters that had a statistically significant score (FDR- adjusted P value <0.05) compared to randomly generated signatures (Methods). Clusters that are naïve-like, effector-like, and memory-precursor-like (Fig. 6E) are indicated by the colored bars.

Figure S5 (Related to Figure 7). Analysis of Tcf7/Tcf1 expression in PD-1 CD8 + TIL subsets and thymic development and peripheral homeostasis in E8i-Cre + Tcf7 fl/fl mice. A) Mean fluorescence intensity (MFI; mean ± SEM) of Tcf1 protein (encoded by Tcf7) in the indicated populations of PD-1 CD8 + TILs. *p < 0.05, **p < 0.01, ****p < 0.0001, One-way ANOVA, Tukey s multiple comparison test. B) Representative FACS plots showing CD4 and CD8 expression in the thymus (top) and spleen (bottom) of E8i-Cre Tcf7 fl/fl vs E8i-Cre + Tcf7 fl/fl mice (n = 3 per group).

Figure S6 (Related to Figure 7). Tumor-antigen specific CD8 + TILs in the absence of Tcf7 and tumor regression in TLR9 agonist treated mice A) E8i-Cre Tcf7 fl/fl and E8i-Cre + Tcf7 fl/fl were implanted with MC38-OVA and TILs analyzed 10 12 days post implant. Frequency (mean ± SEM) of Ova-specific cells in PD1 + and PD1 CD8 + TILs in E8i-Cre Tcf7 fl/fl and E8i-Cre + Tcf7 fl/fl mice is shown. *p < 0.05, ***p < 0.001, t-test. B) WT mice were implanted with MC38-OVA and treated with PBS (blue) or TLR9 agonist (red; IMO-2125) on days 4 and 7. Tumor size (mean ± SEM, top) and individual tumor size (bottom) in each group is shown. ****p < 0.0001, linear regression. Data are representative of at least three independent experiments.

2024 © healthdocbox.com Privacy Policy | Terms of Service | Feedback